BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 21258416)

  • 1. TAZ is a novel oncogene in non-small cell lung cancer.
    Zhou Z; Hao Y; Liu N; Raptis L; Tsao MS; Yang X
    Oncogene; 2011 May; 30(18):2181-6. PubMed ID: 21258416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TAZ activation by Hippo pathway dysregulation induces cytokine gene expression and promotes mesothelial cell transformation.
    Matsushita A; Sato T; Mukai S; Fujishita T; Mishiro-Sato E; Okuda M; Aoki M; Hasegawa Y; Sekido Y
    Oncogene; 2019 Mar; 38(11):1966-1978. PubMed ID: 30401981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TAZ is an independent prognostic factor in non-small cell lung carcinoma: Elucidation at protein level.
    Malik SA; Khan MS; Dar M; Hussain MU; Mudassar S
    Cancer Biomark; 2017; 18(4):389-395. PubMed ID: 28128737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of TAZ expression in resected non-small cell lung cancer.
    Xie M; Zhang L; He CS; Hou JH; Lin SX; Hu ZH; Xu F; Zhao HY
    J Thorac Oncol; 2012 May; 7(5):799-807. PubMed ID: 22481233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TAZ inhibition restores sensitivity of cisplatin via AKT/mTOR signaling in lung adenocarcinoma.
    Xu W; Wei Y; Li Y; Yin Y; Yuan W; Yang Y; Zhao W; Wu J
    Oncol Rep; 2017 Sep; 38(3):1815-1821. PubMed ID: 28737828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rottlerin exhibits antitumor activity via down-regulation of TAZ in non-small cell lung cancer.
    Zhao Z; Zheng N; Wang L; Hou Y; Zhou X; Wang Z
    Oncotarget; 2017 Jan; 8(5):7827-7838. PubMed ID: 27999199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Taxol resistance in breast cancer cells is mediated by the hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF.
    Lai D; Ho KC; Hao Y; Yang X
    Cancer Res; 2011 Apr; 71(7):2728-38. PubMed ID: 21349946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Curcumin suppresses the stemness of non-small cell lung cancer cells via promoting the nuclear-cytoplasm translocation of TAZ.
    Zheng Y; Yang X; Tan J; Tian R; Shen P; Cai W; Liao H
    Environ Toxicol; 2021 Jun; 36(6):1135-1142. PubMed ID: 33539684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SKIL facilitates tumorigenesis and immune escape of NSCLC via upregulating TAZ/autophagy axis.
    Ma F; Ding MG; Lei YY; Luo LH; Jiang S; Feng YH; Liu XL
    Cell Death Dis; 2020 Dec; 11(12):1028. PubMed ID: 33268765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Panobinostat sensitizes KRAS-mutant non-small-cell lung cancer to gefitinib by targeting TAZ.
    Lee WY; Chen PC; Wu WS; Wu HC; Lan CH; Huang YH; Cheng CH; Chen KC; Lin CW
    Int J Cancer; 2017 Nov; 141(9):1921-1931. PubMed ID: 28710768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NDFIP1 limits cellular TAZ accumulation via exosomal sorting to inhibit NSCLC proliferation.
    Cheng Y; Lu X; Li F; Chen Z; Zhang Y; Han Q; Zeng Q; Wu T; Li Z; Lu S; Williams C; Xia W
    Protein Cell; 2023 Mar; 14(2):123-136. PubMed ID: 36929005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A kinome-wide screen using a NanoLuc LATS luminescent biosensor identifies ALK as a novel regulator of the Hippo pathway in tumorigenesis and immune evasion.
    Nouri K; Azad T; Lightbody E; Khanal P; Nicol CJ; Yang X
    FASEB J; 2019 Nov; 33(11):12487-12499. PubMed ID: 31431076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An integrative analysis of the tumorigenic role of TAZ in human non-small cell lung cancer.
    Noguchi S; Saito A; Horie M; Mikami Y; Suzuki HI; Morishita Y; Ohshima M; Abiko Y; Mattsson JS; König H; Lohr M; Edlund K; Botling J; Micke P; Nagase T
    Clin Cancer Res; 2014 Sep; 20(17):4660-72. PubMed ID: 24951773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The candidate oncogene (MCRS1) promotes the growth of human lung cancer cells via the miR-155-Rb1 pathway.
    Liu M; Zhou K; Huang Y; Cao Y
    J Exp Clin Cancer Res; 2015 Oct; 34():121. PubMed ID: 26467212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-582-5p Is a Tumor Suppressor microRNA Targeting the Hippo-YAP/TAZ Signaling Pathway in Non-Small Cell Lung Cancer.
    Zhu B; V M; Finch-Edmondson M; Lee Y; Wan Y; Sudol M; DasGupta R
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33670427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Icariin stimulates osteogenic differentiation of rat bone marrow stromal stem cells by increasing TAZ expression.
    Wei Q; He M; Chen M; Chen Z; Yang F; Wang H; Zhang J; He W
    Biomed Pharmacother; 2017 Jul; 91():581-589. PubMed ID: 28486190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ETS (E26 transformation-specific) up-regulation of the transcriptional co-activator TAZ promotes cell migration and metastasis in prostate cancer.
    Liu CY; Yu T; Huang Y; Cui L; Hong W
    J Biol Chem; 2017 Jun; 292(22):9420-9430. PubMed ID: 28408625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Restoration of Wnt-7a expression reverses non-small cell lung cancer cellular transformation through frizzled-9-mediated growth inhibition and promotion of cell differentiation.
    Winn RA; Marek L; Han SY; Rodriguez K; Rodriguez N; Hammond M; Van Scoyk M; Acosta H; Mirus J; Barry N; Bren-Mattison Y; Van Raay TJ; Nemenoff RA; Heasley LE
    J Biol Chem; 2005 May; 280(20):19625-34. PubMed ID: 15705594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. YAP and TAZ modulate cell phenotype in a subset of small cell lung cancer.
    Horie M; Saito A; Ohshima M; Suzuki HI; Nagase T
    Cancer Sci; 2016 Dec; 107(12):1755-1766. PubMed ID: 27627196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TbetaRIII suppresses non-small cell lung cancer invasiveness and tumorigenicity.
    Finger EC; Turley RS; Dong M; How T; Fields TA; Blobe GC
    Carcinogenesis; 2008 Mar; 29(3):528-35. PubMed ID: 18174241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.